2-(1-氨基乙基)苯甲酸盐酸盐 | 658683-12-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(1-氨基乙基)苯甲酸盐酸盐
• 英文名称: 2-(1-aminoethyl)benzoic acid hydrochloride
• 英文别名: 2-(1-Amino-ethyl)-benzoic acid hydrochloride salt；2-(1-aminoethyl)benzoic acid;hydrochloride
• CAS: 658683-12-6
• 化学式: C₉H₁₁NO₂*ClH
• 分子量: 201.653
• InChiKey: GEYYPUHNSHAXET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.83
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  在 盐酸 、 水 作用下， 以 乙醚 为溶剂， 以37.8 mg的产率得到2-(1-氨基乙基)苯甲酸盐酸盐
  参考文献：
  名称：

  通过羧基介导的分子内 C-H 胺化自由基级联合成 γ-氨基酸或 γ-内酰胺

  摘要：

  羧酸的γC-H胺化为合成高价值医药化学品提供了一种有前途且可持续的策略。由芳酰氧基参与的氢原子转移（HAT）引发的自由基反应途径为远程C-H官能化提供了多样化但具有挑战性的机会。在本报告中，实现了使用市售肟助剂对羧酸进行分子内 γ C-H 胺化的第一个例子。这种创新方法采用自由基中继分子伴侣，通过1,5-HAT/自由基交叉偶联促进选择性 C-H 官能化，并实现氨在羧酸的 γ 碳上的净结合。此外，该方案还可以回收副产物二苯甲酮，并且产物分离和副产物回收均无需硅胶。该反应具有高化学和区域选择性，在温和的反应条件下进行，具有广泛的底物范围，表现出良好的官能团兼容性，并且易于扩展。

  DOI：

  10.1039/d4gc03057e

文献信息

• [EN] CHELATED PSMA INHIBITORS<br/>[FR] INHIBITEURS CHÉLATÉS DU PSMA
  申请人：CANCER TARGETED TECHNOLOGY LLC

  公开号：WO2012174136A1

  公开（公告）日：2012-12-20

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文定义的化合物可用于：（1）用于检测和/或鉴定表达PSMA的细胞的诊断方法；（2）包含本发明化合物的与药用稀释剂一起的组合物；以及（3）用于成像前列腺癌细胞的方法。
• Therapeutic use of aryl amino acid derivatives
  申请人：——

  公开号：US20040138197A1

  公开（公告）日：2004-07-15

  The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 1 wherein R 1 is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; X is —(CH 2 ) n —C(R 7 )(R 8 )—; Y is a direct link or —(CH 2 ) m —C(R 9 )(R 10 )—; R 7 , R 8 , R 9 and R 10 are independently H or C 1 -C 6 alkyl; or R 8 and R 1 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 10 and R 1 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 8 and R 10 can be taken together with the carbons to which they are attached to form a 4-8-membered carbocyclic ring; n is 0, 1 or 2; m is 0, 1 or 2; R 2 , R 3 , R 4 and R 5 are independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, halogen, hydroxycarbonyl, C 1 -C 6 alkoxycarbonyl, cyano, sulfonyl, C 1 -C 6 alkylsulfonyl, thio, C 1 -C 6 alkylthio, sulfonamide, perfluoro-C 1 -C 6 alkyl, perfluoro-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, amino, (C 1 -C 6 alkyl or di-C 1 -C 6 alkyl)amino, aminocarbonyl, (C 1 -C 6 alkyl or di-C 1 -C 6 alkyl)aminocarbonyl, C 1 -C 6 acylamino, (N—C 1 -C 6 alkyl)C 1 -C 6 acylamino, phenyl or monocyclic heteroaryl, wherein phenyl and monocyclic heteroaryl are optionally substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, halogen, hydroxycarbonyl, C 1 -C 6 alkoxycarbonyl or perfluoro-C 1 -C 6 alkoxy; or any one or two of CR 2 , CR 3 , CR 4 and CR 5 may be replaced with a nitrogen; or R 2 and R 3 or R 3 and R 4 or R 4 and R 5 may be taken together with the carbons to which they are attached to form fused C 5 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl or monocyclic heteroaryl; or R 1 and R 2 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 8 and R 2 can be taken together with the carbons to which they are attached to form a 4-8-membered carbocyclic or heterocycloalkyl ring; and R 6 is hydroxycarbonyl or a carboxylic acid biostere or a prodrug thereof.

  式(I)的化合物在治疗晕厥发作、运动减退、头颅疾病、神经退行性疾病、抑郁症、焦虑、恐慌、神经病理性疼痛、神经病理性疾病和睡眠障碍方面有用。包括制备最终产品和在过程中有用的中间体的过程。还包括含有一种或多种化合物的制药组合物。其中，R1为H、C1-C6烷基或C3-C8环烷基；X为—(CH2)n—C(R7)(R8)—；Y为直接连接或—( )m—C(R9)(R10)—；R7、R8、R9和R10独立地为H或C1-C6烷基；或R8和R1可以与R1连接的氮一起形成4-8环杂环烷基环；或R10和R1可以与R1连接的氮一起形成4-8环杂环烷基环；或R8和R10可以与它们连接的碳一起形成4-8环碳杂环烷基环；n为0、1或2；m为0、1或2；R2、R3、R4和R5独立地选自H、C1-C6烷基、C1-C6烷氧基、羟基、卤素、羟基羧酸、C1-C6烷氧羰基、氰基、磺酰基、C1-C6烷基磺酰基、硫基、C1-C6烷基硫基、磺酰胺基、全氟C1-C6烷基、全氟C1-C6烷氧基、C3-C8环烷基、4-8环杂环烷基、氨基、(C1-C6烷基或二-C1-C6烷基)氨基、氨基羧酸、(C1-C6烷基或二-C1-C6烷基)氨基羧酸、C1-C6酰胺基、(N-C1-C6烷基)C1-C6酰胺基、苯基或单环杂芳基，其中苯基和单环杂芳基可选择性地被C1-C6烷基、C1-C6烷氧基、羟基、卤素、羟基羧酸、C1-C6烷氧羰基或全氟C1-C6烷氧基取代；或CR2、CR3、CR4和CR5中的任意一个或两个可以被氮取代；或R2和R3或R3和R4或R4和R5可以与它们连接的碳一起形成融合的C5-C8环烷基、4-8环杂环烷基、苯基或单环杂芳基；或R1和R2可以与R1连接的氮一起形成4-8环杂环烷基环；或R8和R2可以与它们连接的碳一起形成4-8环碳杂环烷基环或杂环烷基环；R6为羟基羧酸或羧酸生物立体异构体或其前药。
• CHELATED PSMA INHIBITORS
  申请人：Cancer Targeted Technology LLC

  公开号：EP2721039A1

  公开（公告）日：2014-04-23
• US7053122B2
  申请人：——

  公开号：US7053122B2

  公开（公告）日：2006-05-30
• [EN] TRIPHENYLPHOSPHONIUM BIGUANIDE ANALOGUES, THEIR METHOD OF PREPARATION AND USE AS DRUGS<br/>[FR] ANALOGUES DE BIGUANIDE DE TRIPHÉNYLPHOSPHONIUM, LEUR PROCÉDÉ DE PRÉPARATION ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：KKCG SE

  公开号：WO2016155679A1

  公开（公告）日：2016-10-06

  The present invention provides triphenylphosphonium biguanide analogs of general formula (I), whereas the general formula (I) includes resonance structures and pharmaceutically acceptable salts, protonated form as well as free base, (Formula (I)) where each one of R1, R2, R3, R4, R5, R6, R7 is independently selected from the group comprising H; C1-C6 alkyl; C6-C10 aryl; (C1-C6)alkyl(C6-C10)aryl; -C(=O)-R'; -C(=O)OR'; -C(=O)NR'R"; -C(=S)R'; -C(=S)NR'R''; wherein R' and R" are independently selected from the group comprising H, C1-C6 alkoxy, C1-C6 alkyl, C6-C10aryl, (Cl-C6)alkyl(C6-C10)aryl; whereas C1-C6 alkoxy, C1-C6 alkyl, C6-C10 aryl, (C1-C6)alkyl(C6-C10)aryl can be unsubstituted or substituted by one or more substituents selected independently from the group comprising C1-C4 alkyl, N(H or C1-C4 alkyl)2, wherein alkyls are the same or different, phenyl, benzyl, OH, SH, F, CI, Br, I, C1-C4alkoxy, C1-C4 acyloxy, C1-C4 mercapto; and substituent of general formula (II) (Formula (I)) wherein Z is as defined in the claims, whereas at least one of R1, R2, R3, R4, R5, R6, R7 is the substituent of general formula (II), X- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid, Y- is a pharmaceutically acceptable anion, preferably an anion of inorganic or organic acid. The invention further provides a method of preparation of these derivatives. These new compounds are suitable in particular for the treatment of diabetes mellitus type 2 and/or pancreatic carcinoma.